Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback